Literature DB >> 16148458

GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat.

Laura Dugo1, Marika Collin, David A Allen, Nimesh S A Patel, Inge Bauer, Eero M A Mervaala, Marjut Louhelainen, Simon J Foster, Muhammad M Yaqoob, Christoph Thiemermann.   

Abstract

OBJECTIVE: Serine-threonine protein kinase glycogen synthase kinase (GSK)-3 is involved in regulation of many cell functions, but its role in regulation of inflammatory response is unknown. Here we investigate the effects of GSK-3beta inhibition on organ injury/dysfunction caused by lipopolysaccharide or coadministration of lipopolysaccharide and peptidoglycan in the rat.
DESIGN: Prospective, randomized study.
SETTING: University-based research laboratory.
SUBJECTS: Ninety-nine anesthetized male Wistar rats.
INTERVENTIONS: Study 1: Rats received either intravenous Escherichia coli lipopolysaccharide (6 mg/kg) or vehicle (1 mL/kg; saline). Study 2: Rats received either intravenous E. coli lipopolysaccharide (1 mg/kg) and Staphylococcus aureus peptidoglycan (0.3 mg/kg) or vehicle. The potent and selective GSK-3beta inhibitors TDZD-8 (1 mg/kg intravenously), SB216763 (0.6 mg/kg intravenously), and SB415286 (1 mg/kg intravenously) or vehicle (10% dimethyl sulfoxide) was administered 30 mins before lipopolysaccharide or lipopolysaccharide and peptidoglycan.
MEASUREMENTS AND MAIN RESULTS: Endotoxemia resulted in increases in the serum levels of creatinine (indicator of renal dysfunction), aspartate aminotransferase, alanine aminotransferase (markers for hepatocellular injury), lipase (indicator of pancreatic injury), and creatine kinase (indicator of neuromuscular injury). Coadministration of lipopolysaccharide and peptidoglycan resulted in hepatocellular injury and renal dysfunction. All GSK-3beta inhibitors attenuated the organ injury/dysfunction caused by lipopolysaccharide or lipopolysaccharide and peptidoglycan. GSK-3beta inhibition reduced the Ser536 phosphorylation of nuclear factor-kappaB subunit p65 and the messenger RNA expression of nuclear factor-kappaB-dependent proinflammatory mediators but had no effect on the nuclear factor-kappaB/DNA binding activity in the lung. GSK-3beta inhibition reduced the increase in nuclear factor-kappaB p65 activity caused by interleukin-1 in human embryonic kidney cells in vitro.
CONCLUSIONS: The potent and selective GSK-3beta inhibitors TDZD-8, SB216763, and SB415286 reduced the organ injury/dysfunction caused by lipopolysaccharide or lipopolysaccharide and peptidoglycan in the rat. We propose that GSK-3beta inhibition may be useful in the therapy of the organ injury/dysfunction associated with sepsis, shock, and other diseases associated with local or systemic inflammation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16148458     DOI: 10.1097/01.ccm.0000178350.21839.44

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  54 in total

1.  Inhibition of glycogen synthase kinase 3[beta] activity with lithium in vitro attenuates sepsis-induced changes in muscle protein turnover.

Authors:  Stephen Bertsch; Charles H Lang; Thomas C Vary
Journal:  Shock       Date:  2011-03       Impact factor: 3.454

2.  Suppressive regulatory T cell activity is potentiated by glycogen synthase kinase 3{beta} inhibition.

Authors:  Jay A Graham; Michael Fray; Stephanie de Haseth; Kang Mi Lee; Moh-Moh Lian; Catharine M Chase; Joren C Madsen; James Markmann; Gilles Benichou; Robert B Colvin; A Benedict Cosimi; Shaoping Deng; James Kim; Alessandro Alessandrini
Journal:  J Biol Chem       Date:  2010-08-20       Impact factor: 5.157

Review 3.  Remote ischemic preconditioning for kidney protection: GSK3β-centric insights into the mechanism of action.

Authors:  Zhangsuo Liu; Rujun Gong
Journal:  Am J Kidney Dis       Date:  2015-08-10       Impact factor: 8.860

4.  Lysophosphatidylcholine reduces the organ injury and dysfunction in rodent models of gram-negative and gram-positive shock.

Authors:  Oliver Murch; Marika Collin; Bruno Sepodes; Simon J Foster; Helder Mota-Filipe; Christoph Thiemermann
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

Review 5.  Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.

Authors:  Richard S Jope; Christopher J Yuskaitis; Eléonore Beurel
Journal:  Neurochem Res       Date:  2006-08-30       Impact factor: 3.996

6.  Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis and RANTES production in microglial cells.

Authors:  Wei-Ching Huang; Yee-Shin Lin; Chi-Yun Wang; Cheng-Chieh Tsai; Hsiang-Chi Tseng; Chia-Ling Chen; Pei-Jung Lu; Po-See Chen; Li Qian; Jau-Shyong Hong; Chiou-Feng Lin
Journal:  Immunology       Date:  2008-10-29       Impact factor: 7.397

7.  Lithium prevents and ameliorates experimental autoimmune encephalomyelitis.

Authors:  Patrizia De Sarno; Robert C Axtell; Chander Raman; Kevin A Roth; Dario R Alessi; Richard S Jope
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

8.  Inhibition of glycogen synthase kinase 3beta (GSK3beta) decreases inflammatory responses in brain endothelial cells.

Authors:  Servio H Ramirez; Shongshan Fan; Ming Zhang; Anil Papugani; Nancy Reichenbach; Holly Dykstra; Aaron J Mercer; Ronald F Tuma; Yuri Persidsky
Journal:  Am J Pathol       Date:  2010-01-07       Impact factor: 4.307

Review 9.  Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3).

Authors:  Eléonore Beurel; Suzanne M Michalek; Richard S Jope
Journal:  Trends Immunol       Date:  2009-10-14       Impact factor: 16.687

10.  Rho iso-alpha acids from hops inhibit the GSK-3/NF-kappaB pathway and reduce inflammatory markers associated with bone and cartilage degradation.

Authors:  Veera Reddy Konda; Anuradha Desai; Gary Darland; Jeffrey S Bland; Matthew L Tripp
Journal:  J Inflamm (Lond)       Date:  2009-08-27       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.